309 related articles for article (PubMed ID: 30139383)
1. Epigenetic regulation of ID4 in breast cancer: tumor suppressor or oncogene?
Nasif D; Campoy E; Laurito S; Branham R; Urrutia G; Roqué M; Branham MT
Clin Epigenetics; 2018 Aug; 10(1):111. PubMed ID: 30139383
[TBL] [Abstract][Full Text] [Related]
2. CDC42 as an epigenetic regulator of ID4 in triple-negative breast tumors.
Nasif D; Real S; Roqué M; Branham MT
Breast Cancer; 2022 May; 29(3):562-573. PubMed ID: 35094293
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer.
Carey JP; Asirvatham AJ; Galm O; Ghogomu TA; Chaudhary J
BMC Cancer; 2009 Jun; 9():173. PubMed ID: 19500415
[TBL] [Abstract][Full Text] [Related]
4. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer.
Noetzel E; Veeck J; Niederacher D; Galm O; Horn F; Hartmann A; Knüchel R; Dahl E
BMC Cancer; 2008 May; 8():154. PubMed ID: 18513385
[TBL] [Abstract][Full Text] [Related]
6. [Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer].
Noetzel E; Veeck J; Horn F; Hartmann A; Knüchel R; Dahl E
Pathologe; 2008 Nov; 29 Suppl 2():319-27. PubMed ID: 18807039
[TBL] [Abstract][Full Text] [Related]
7. miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.
Crippa E; Lusa L; De Cecco L; Marchesi E; Calin GA; Radice P; Manoukian S; Peissel B; Daidone MG; Gariboldi M; Pierotti MA
PLoS One; 2014; 9(1):e87039. PubMed ID: 24475217
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
Branham MT; Campoy E; Laurito S; Branham R; Urrutia G; Orozco J; Gago F; Urrutia R; Roqué M
Breast Cancer Res Treat; 2016 Jan; 155(1):13-23. PubMed ID: 26610810
[TBL] [Abstract][Full Text] [Related]
9. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
11. Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas.
Bjørklund SS; Kristensen VN; Seiler M; Kumar S; Alnæs GI; Ming Y; Kerrigan J; Naume B; Sachidanandam R; Bhanot G; Børresen-Dale AL; Ganesan S
BMC Cancer; 2015 Jul; 15():524. PubMed ID: 26183823
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer.
Sharma P; Chinaranagari S; Patel D; Carey J; Chaudhary J
Cancer Med; 2012 Oct; 1(2):176-86. PubMed ID: 23342267
[TBL] [Abstract][Full Text] [Related]
13. Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer.
Roldán G; Delgado L; Musé IM
Cancer Biol Ther; 2006 May; 5(5):505-10. PubMed ID: 16582598
[TBL] [Abstract][Full Text] [Related]
14. MGP is downregulated due to promoter methylation in chemoresistant ER+ breast cancer and high MGP expression predicts better survival outcomes.
Tuo YL; Ye YF
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3871-3878. PubMed ID: 28975977
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5-aza-2'-deoxycytosine with potential therapeutic significance in Burkitt's lymphoma.
Gao XZ; Zhao WG; Wang GN; Cui MY; Zhang YR; Li WC
Mol Med Rep; 2016 Feb; 13(2):1269-74. PubMed ID: 26648013
[TBL] [Abstract][Full Text] [Related]
16. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
Wolf I; O'Kelly J; Rubinek T; Tong M; Nguyen A; Lin BT; Tai HH; Karlan BY; Koeffler HP
Cancer Res; 2006 Aug; 66(15):7818-23. PubMed ID: 16885386
[TBL] [Abstract][Full Text] [Related]
17. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer.
Umetani N; Mori T; Koyanagi K; Shinozaki M; Kim J; Giuliano AE; Hoon DS
Oncogene; 2005 Jul; 24(29):4721-7. PubMed ID: 15897910
[TBL] [Abstract][Full Text] [Related]
18. Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles.
Campoy EM; Branham MT; Mayorga LS; Roqué M
BMC Cancer; 2019 Apr; 19(1):328. PubMed ID: 30953488
[TBL] [Abstract][Full Text] [Related]
19. Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.
Donzelli S; Milano E; Pruszko M; Sacconi A; Masciarelli S; Iosue I; Melucci E; Gallo E; Terrenato I; Mottolese M; Zylicz M; Zylicz A; Fazi F; Blandino G; Fontemaggi G
Breast Cancer Res; 2018 Jun; 20(1):59. PubMed ID: 29921315
[TBL] [Abstract][Full Text] [Related]
20. UVB induces cutaneous squamous cell carcinoma progression by de novo ID4 methylation via methylation regulating enzymes.
Li L; Li F; Xia Y; Yang X; Lv Q; Fang F; Wang Q; Bu W; Wang Y; Zhang K; Wu Y; Shen J; Jiang M
EBioMedicine; 2020 Jul; 57():102835. PubMed ID: 32574963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
